The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group

R. W. Evans, B. Rader and D. L. Manninen
Battelle Seattle Research Center, WA 98105.

Initial clinical trials with recombinant human erythropoietin provided evidence of a quality-of-life benefit for patients with anemic end-stage renal disease who received maintenance hemodialysis. As part of a phase III clinical trial of recombinant human erythropoietin, the quality of life of patients was systematically assessed. More than 300 patients at nine dialysis centers were evaluated. A statistically significant improvement was established between baseline and second follow-up on most objective and subjective quality-of-life parameters, including energy and activity level, functional ability, sleep and eating behavior, disease symptoms, health status, satisfaction with health, sex life, well-being, psychological affect, life satisfaction, and happiness. No change was observed in ability to work or employment status. We conclude that, in addition to substantial improvement in hematologic parameters, recombinant human erythropoietin greatly enhances the quality of life of anemic patients who receive maintenance hemodialysis.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Psychometric evaluation of the National Kidney Dialysis and Kidney Transplantation Study symptom checklist: reliability and validity
Spiegel et al.
Nephrol Dial Transplant 2008;0:gfn523v1-gfn523.
ABSTRACT | FULL TEXT  

Anemia of Chronic Kidney Disease
Singh
CJASN 2008;3:3-6.
FULL TEXT  

Reducing versus Discontinuing Erythropoietin at High Hemoglobin Levels
Weiner et al.
J. Am. Soc. Nephrol. 2007;18:3184-3191.
ABSTRACT | FULL TEXT  

Development of a Long-Acting Erythropoietin by Fusing the Carboxyl-Terminal Peptide of Human Chorionic Gonadotropin {beta}-Subunit to the Coding Sequence of Human Erythropoietin
Fares et al.
Endocrinology 2007;148:5081-5087.
ABSTRACT | FULL TEXT  

Once-Monthly Subcutaneous C.E.R.A. Maintains Stable Hemoglobin Control in Patients with Chronic Kidney Disease on Dialysis and Converted Directly from Epoetin One to Three Times Weekly
Sulowicz et al.
CJASN 2007;2:637-646.
ABSTRACT | FULL TEXT  

Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity
Bovy et al.
Nephrol Dial Transplant 2007;22:1156-1162.
ABSTRACT | FULL TEXT  

Iron treatment normalizes cognitive functioning in young women
Murray-Kolb and Beard
Am. J. Clin. Nutr. 2007;85:778-787.
ABSTRACT | FULL TEXT  

Reply
Jacob
Nephrol Dial Transplant 2007;22:963-963.
FULL TEXT  

Epoetin Alfa Once Every 2 Weeks Is Effective for Initiation of Treatment of Anemia of Chronic Kidney Disease
Benz et al.
CJASN 2007;2:215-221.
ABSTRACT | FULL TEXT  

Longitudinal validation of a modified Edmonton symptom assessment system (ESAS) in haemodialysis patients
Davison et al.
Nephrol Dial Transplant 2006;21:3189-3195.
ABSTRACT | FULL TEXT  

Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review
Germain et al.
Nephrol Dial Transplant 2005;20:2146-2152.
ABSTRACT | FULL TEXT  

Prospective Study of the Immune Effects of Normalizing the Hemoglobin Concentration in Hemodialysis Patients Who Receive Recombinant Human Erythropoietin
Roman et al.
J. Am. Soc. Nephrol. 2004;15:1339-1346.
ABSTRACT | FULL TEXT  

Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients
Jadoul et al.
Nephrol Dial Transplant 2004;19:898-903.
ABSTRACT | FULL TEXT  

Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
Locatelli et al.
Nephrol Dial Transplant 2004;19:121-132.
ABSTRACT | FULL TEXT  

Left ventricular hypertrophy: a surrogate end point or correlate of cardiovascular events in kidney disease?
Griffith et al.
Nephrol Dial Transplant 2003;18:2479-2482.
FULL TEXT  

Protocolized Anemia Management with Erythropoietin in Hemodialysis Patients: A Randomized Controlled Trial
Brimble et al.
J. Am. Soc. Nephrol. 2003;14:2654-2661.
ABSTRACT | FULL TEXT  

Impact of Quality Improvement Efforts on Race and Sex Disparities in Hemodialysis
Sehgal
JAMA 2003;289:996-1000.
ABSTRACT | FULL TEXT  

Association of Kidney Function With Anemia: The Third National Health and Nutrition Examination Survey (1988-1994)
Astor et al.
Arch Intern Med 2002;162:1401-1408.
ABSTRACT | FULL TEXT  

Health-related quality of life assessment in end-stage renal failure
Piillips et al.
Journal of Research in Nursing 2001;6:658-670.
ABSTRACT  

Left Ventricular Hypertrophy in the Renal Patient
MIDDLETON et al.
J. Am. Soc. Nephrol. 2001;12:1079-1084.
FULL TEXT  

Management of anaemia in United Kingdom renal units: a report from the UK Renal Registry
Burton et al.
Nephrol Dial Transplant 2000;15:1022-1028.
ABSTRACT | FULL TEXT  

Increasing the Hematocrit Has a Beneficial Effect on Quality of Life and Is Safe in Selected Hemodialysis Patients
MORENO et al.
J. Am. Soc. Nephrol. 2000;11:335-342.
ABSTRACT | FULL TEXT  

Is there material hazard to treatment with intravenous iron?
Fishbane et al.
Nephrol Dial Transplant 1999;14:2595-2598.
FULL TEXT  

Quality of Life and Pain in Patients With Recurrent Breast and Gynecologic Cancer
Rummans et al.
Psychosomatics 1998;39:437-445.
ABSTRACT | FULL TEXT  

The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin
Besarab et al.
NEJM 1998;339:584-590.
ABSTRACT | FULL TEXT  

ERYTHROPOIETIN IMPROVES QUALITY OF LIFE FOR DIALYSIS PATIENTS
JWatch General 1990;1990:3-3.
FULL TEXT